Lipid Modifying Agents, Plain

DrugDrug NameDrug Indication
DB00375ColestipolColestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia (a condition that features elevated LDL-C) who do not respond adequately to diet [FDA Label, L6115, F4555]. Therapy with lipid-altering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia [FDA Label, L6115, F4555]. Treatment should begin and continue with dietary therapy [FDA Label, L6115, F4555]. In general, a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol [FDA Label, F4555]. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite coronary heart disease [FDA Label, F4555]. Although colestipol is effective in all types of hypercholesterolemia, some regional prescribing information note in particular that it is medically most appropriate in patients with Fredrickson's type II hyperlipoproteinemia [L6115]. Nevertheless, in patients with combined hypercholesterolemia and hypertriglyceridemia, although colestipol may be helpful in reducing elevated cholesterol, it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern [F4567].
DB00439CerivastatinUsed as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
DB00509DextrothyroxineUsed to lower high cholesterol levels in the blood.
DB00636ClofibrateFor Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels.
DB00930ColesevelamFor use, alone or in combination with an HMG-CoA reductase inhibitor, as adjunctive therapy to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa).
DB01095FluvastatinTo be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.
DB01241GemfibrozilFor treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.
DB01393BezafibrateFor the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).
DB01432CholestyramineIndicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.
DB01599ProbucolUsed to lower LDL and HDL cholesterol.
DB05528MipomersenUsed in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
DB08827LomitapideUsed in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
DB08860PitavastatinPitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). It is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated TC, LDL-C, and Apo B.[F4667] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB08983EtofibrateNot Available
DB09055AcipimoxUsed in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).
DB09064CiprofibrateNot Available
DB09303EvolocumabFor the treatment of heterozygous/homozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional LDL-cholesterol lowering.
DB13348TiadenolNot Available
DB13422NicofuranoseNot Available
DB13433SimfibrateNot Available
DB13441NiceritrolNot Available
DB13460RonifibrateNot Available
DB13521Alipogene tiparvovecNot Available
DB13576Aluminium nicotinateNot Available
DB13780Aluminium clofibrateNot Available
DB13849ClofibrideNot Available
DB13873Fenofibric acidFor use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). [FDA Label]
DB00175PravastatinPravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.[T274] As well, pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease. This indication includes the reduction of risk of total mortality by reducing coronary death, myocardial infarction, undergoing myocardial revascularization procedures, stroke, and stroke/transient ischemic attack as well as to slow the progression of coronary atherosclerosis.[T274] The term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flow.[L6028] As adjunctive therapy to diet, pravastatin is used in: - Patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type IIa and IIb. - Patients with elevated serum triglycerides including type IV hyperlipidemia. - Patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with low-density lipoprotein (LDL) cholesterol higher than 190 mg/dl after diet modifications or LDL levels higher than 160 mg/dl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factors.[T274] In patients that do not respond adequately to diet, pravastatin is used to treat patients with primary dysbetalipoproteinemia (type III hyperlipidemia).[T274] Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025]
DB00627NiacinNiacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]
DB00641SimvastatinSimvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658] This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658] Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB00973EzetimibeEzetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin), reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin, and to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia) [FDA Label].
DB01039FenofibrateFor use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
DB01076AtorvastatinAtorvastatin is approved for the treatment of several types of dyslipidemias including: - Primary hyperlipidemia and mixed dyslipidemia in adults. - Hypertriglyceridemia. - Primary dysbetalipoproteinemia. - Homozygous familial hypercholesterolemia. - Heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397] Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397] Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors, and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397] Atorvastatin can also be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB01098RosuvastatinThe FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.[F4649] The Health Canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate. It is also indicated for the prevention of major cardiovascular events (including risk of myocardial infarction, nonfatal stroke, and coronary artery revascularization) in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.[F4652] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB04145Nicotinyl alcoholNot Available
DB04377MeglutolNot Available
DB09302AlirocumabAlirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor activity that is indicated for: (i) use in reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease [F4591], and/or (ii) use as an adjunct to diet or use alone or in combination with other lipid-lowering therapies (statins, ezetimibe, for example) for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C) levels in the body [F4591].
DrugDrug NameTargetType
DB00375ColestipolBile acidstarget
DB00439Cerivastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00439CerivastatinCytochrome P450 2C8enzyme
DB00439CerivastatinCytochrome P450 3A4enzyme
DB00439CerivastatinCytochrome P450 2D6enzyme
DB00439CerivastatinCytochrome P450 2C9enzyme
DB00439CerivastatinCytochrome P450 3A5enzyme
DB00439CerivastatinCytochrome P450 3A7enzyme
DB00439CerivastatinMultidrug resistance protein 1transporter
DB00439CerivastatinCanalicular multispecific organic anion transporter 1transporter
DB00439CerivastatinATP-binding cassette sub-family G member 2transporter
DB00439CerivastatinSolute carrier organic anion transporter family member 1B1transporter
DB00439CerivastatinCytochrome P450 2B6enzyme
DB00439CerivastatinUDP-glucuronosyltransferase 1-1enzyme
DB00439CerivastatinBile salt export pumptransporter
DB00509DextrothyroxineThyroid hormone receptor alphatarget
DB00509DextrothyroxineThyroid hormone receptor betatarget
DB00509DextrothyroxineThyroid peroxidasetarget
DB00509DextrothyroxineSolute carrier organic anion transporter family member 1B1transporter
DB00509DextrothyroxineSolute carrier organic anion transporter family member 1C1transporter
DB00509DextrothyroxineSolute carrier organic anion transporter family member 4A1transporter
DB00509DextrothyroxineSolute carrier organic anion transporter family member 4C1transporter
DB00509DextrothyroxineLarge neutral amino acids transporter small subunit 1transporter
DB00636ClofibratePeroxisome proliferator-activated receptor alphatarget
DB00636ClofibrateCytochrome P450 3A4enzyme
DB00636ClofibrateGlutathione S-transferase A2enzyme
DB00636ClofibrateCytochrome P450 2E1enzyme
DB00636ClofibrateCytochrome P450 1A1enzyme
DB00636ClofibrateCytochrome P450 2A6enzyme
DB00636ClofibrateCytochrome P450 2B6enzyme
DB00636ClofibrateCytochrome P450 4A11enzyme
DB00636ClofibrateThyroxine-binding globulincarrier
DB00930ColesevelamBile acidstarget
DB01095Fluvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01095FluvastatinCytochrome P450 2C9enzyme
DB01095FluvastatinCytochrome P450 3A4enzyme
DB01095FluvastatinCytochrome P450 2C8enzyme
DB01095FluvastatinCytochrome P450 2D6enzyme
DB01095FluvastatinCytochrome P450 2C19enzyme
DB01095FluvastatinCytochrome P450 1A1enzyme
DB01095FluvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01095FluvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01095FluvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01095FluvastatinSolute carrier family 15 member 1transporter
DB01095FluvastatinCytochrome P450 3A5enzyme
DB01095FluvastatinUDP-glucuronosyltransferase 1-1enzyme
DB01095FluvastatinUDP-glucuronosyltransferase 1-3enzyme
DB01095FluvastatinUDP-glucuronosyltransferase 2B7enzyme
DB01095FluvastatinCanalicular multispecific organic anion transporter 1transporter
DB01095FluvastatinCytochrome P450 2B6enzyme
DB01095FluvastatinHistone deacetylase 2target
DB01241GemfibrozilPeroxisome proliferator-activated receptor alphatarget
DB01241GemfibrozilCytochrome P450 2C9enzyme
DB01241GemfibrozilCytochrome P450 2C8enzyme
DB01241GemfibrozilCytochrome P450 1A2enzyme
DB01241GemfibrozilCytochrome P450 2C19enzyme
DB01241GemfibrozilSolute carrier organic anion transporter family member 1B1transporter
DB01241GemfibrozilUDP-glucuronosyltransferase 1-1enzyme
DB01241GemfibrozilCytochrome P450 3A4enzyme
DB01241GemfibrozilUDP-glucuronosyltransferase 1-3enzyme
DB01393BezafibratePeroxisome proliferator-activated receptor alphatarget
DB01393BezafibrateSolute carrier organic anion transporter family member 1B1transporter
DB01393BezafibratePeroxisome proliferator-activated receptor deltatarget
DB01393BezafibratePeroxisome proliferator-activated receptor gammatarget
DB01393BezafibrateCytochrome P450 1A1enzyme
DB01393BezafibrateCytochrome P450 2C8enzyme
DB01393BezafibrateCytochrome P450 3A4enzyme
DB01393BezafibrateNuclear receptor subfamily 1 group I member 2target
DB01393BezafibrateRetinoic acid receptor RXR-alphatarget
DB01393BezafibrateRetinoic acid receptor RXR-betatarget
DB01393BezafibrateRetinoic acid receptor RXR-gammatarget
DB01432CholestyramineBile acidstarget
DB01599ProbucolATP-binding cassette sub-family A member 1target
DB01599ProbucolLiver carboxylesterase 1target
DB05528MipomersenmRNA of ApoB-100target
DB08827LomitapideMicrosomal triglyceride transfer protein large subunittarget
DB08827LomitapideCytochrome P450 3A4enzyme
DB08827LomitapideMultidrug resistance protein 1transporter
DB08860PitavastatinSolute carrier organic anion transporter family member 1B1transporter
DB08860PitavastatinSolute carrier organic anion transporter family member 1B3transporter
DB08860PitavastatinUDP-glucuronosyltransferase 2B7enzyme
DB08860PitavastatinUDP-glucuronosyltransferase 1-3enzyme
DB08860PitavastatinCytochrome P450 2C9enzyme
DB08860PitavastatinCytochrome P450 2C8enzyme
DB08860Pitavastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB08860PitavastatinSolute carrier organic anion transporter family member 2B1transporter
DB08860PitavastatinSodium/bile acid cotransportertransporter
DB08860PitavastatinATP-binding cassette sub-family G member 2transporter
DB08860PitavastatinMultidrug resistance protein 1transporter
DB08860PitavastatinCanalicular multispecific organic anion transporter 1transporter
DB08860PitavastatinSerum albumincarrier
DB08860PitavastatinAlpha-1-acid glycoprotein 1carrier
DB08860PitavastatinBile salt export pumptransporter
DB08860PitavastatinIntegrin alpha-Ltarget
DB09064CiprofibratePeroxisome proliferator-activated receptor alphatarget
DB09303EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DB13873Fenofibric acidPeroxisome proliferator-activated receptor alphatarget
DB13873Fenofibric acidMetalloproteinasetarget
DB13873Fenofibric acidPeroxisome proliferator-activated receptor gammatarget
DB13873Fenofibric acidPeroxisome proliferator-activated receptor deltatarget
DB13873Fenofibric acidNuclear receptor subfamily 1 group I member 2target
DB00175Pravastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00175PravastatinSolute carrier organic anion transporter family member 2B1transporter
DB00175PravastatinMultidrug resistance protein 1transporter
DB00175PravastatinSolute carrier organic anion transporter family member 1A2transporter
DB00175PravastatinSolute carrier family 22 member 6transporter
DB00175PravastatinSolute carrier family 22 member 8transporter
DB00175PravastatinCanalicular multispecific organic anion transporter 1transporter
DB00175PravastatinSolute carrier family 22 member 11transporter
DB00175PravastatinATP-binding cassette sub-family G member 2transporter
DB00175PravastatinSolute carrier family 22 member 7transporter
DB00175PravastatinSolute carrier organic anion transporter family member 1B1transporter
DB00175PravastatinMonocarboxylate transporter 1transporter
DB00175PravastatinBile salt export pumptransporter
DB00175PravastatinSolute carrier organic anion transporter family member 1B3transporter
DB00175PravastatinHistone deacetylase 2target
DB00627NiacinHydroxycarboxylic acid receptor 2target
DB00627NiacinNicotinamide N-methyltransferasetarget
DB00627NiacinNicotinate-nucleotide pyrophosphorylase [carboxylating]target
DB00627NiacinHydroxycarboxylic acid receptor 3target
DB00627NiacinSolute carrier family 22 member 5transporter
DB00627NiacinSolute carrier organic anion transporter family member 2B1transporter
DB00627NiacinMonocarboxylate transporter 1transporter
DB00627NiacinCytochrome P450 2D6enzyme
DB00627NiacinSodium-coupled monocarboxylate transporter 1transporter
DB00627NiacinMonocarboxylate transporter 4transporter
DB00627NiacinThyroxine-binding globulincarrier
DB00627NiacinCytochrome P450 3A4enzyme
DB00627NiacinCytochrome P450 2E1enzyme
DB00641Simvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00641SimvastatinCytochrome P450 3A4enzyme
DB00641SimvastatinCytochrome P450 2C8enzyme
DB00641SimvastatinCytochrome P450 2C9enzyme
DB00641SimvastatinCytochrome P450 3A5enzyme
DB00641SimvastatinMultidrug resistance protein 1transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1A2transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1B1transporter
DB00641SimvastatinCytochrome P450 2B6enzyme
DB00641SimvastatinCytochrome P450 2D6enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 1-1enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 1-3enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 2B7enzyme
DB00641SimvastatinCanalicular multispecific organic anion transporter 1transporter
DB00641SimvastatinIntegrin alpha-Ltarget
DB00641SimvastatinBile salt export pumptransporter
DB00641SimvastatinCytochrome P450 2C19enzyme
DB00641SimvastatinSolute carrier organic anion transporter family member 2B1transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1B3transporter
DB00641SimvastatinHistone deacetylase 2target
DB00973EzetimibeNiemann-Pick C1-like protein 1target
DB00973EzetimibeAminopeptidase Ntarget
DB00973EzetimibeSterol O-acyltransferase 1target
DB00973EzetimibeUDP-glucuronosyltransferase 1-1enzyme
DB00973EzetimibeUDP-glucuronosyltransferase 1-3enzyme
DB00973EzetimibeMultidrug resistance protein 1transporter
DB00973EzetimibeCanalicular multispecific organic anion transporter 1transporter
DB00973EzetimibeSolute carrier organic anion transporter family member 1B1transporter
DB00973EzetimibeUDP-glucuronosyltransferase 2B15enzyme
DB00973EzetimibeUDP-glucuronosyltransferase 2B7enzyme
DB00973EzetimibeCytochrome P450 3A4enzyme
DB00973EzetimibeATP-binding cassette sub-family G member 5transporter
DB00973EzetimibeCanalicular multispecific organic anion transporter 2transporter
DB00973EzetimibeATP-binding cassette sub-family G member 2transporter
DB00973EzetimibeATP-binding cassette sub-family G member 8transporter
DB00973EzetimibeCytochrome P450 2C8enzyme
DB00973EzetimibeBile salt export pumptransporter
DB01039FenofibratePeroxisome proliferator-activated receptor alphatarget
DB01039FenofibrateMetalloproteinasetarget
DB01039FenofibrateCytochrome P450 2C8enzyme
DB01039FenofibrateCytochrome P450 2C9enzyme
DB01039FenofibrateCytochrome P450 3A4enzyme
DB01039FenofibratePeroxisome proliferator-activated receptor gammatarget
DB01039FenofibratePeroxisome proliferator-activated receptor deltatarget
DB01039FenofibrateNuclear receptor subfamily 1 group I member 2target
DB01039FenofibrateUDP-glucuronosyltransferase 1-1enzyme
DB01039FenofibrateBile salt export pumptransporter
DB01076Atorvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01076AtorvastatinCytochrome P450 3A4enzyme
DB01076AtorvastatinDipeptidyl peptidase 4target
DB01076AtorvastatinCytochrome P450 2D6enzyme
DB01076AtorvastatinCytochrome P450 2C9enzyme
DB01076AtorvastatinCytochrome P450 2C19enzyme
DB01076AtorvastatinCytochrome P450 3A5enzyme
DB01076AtorvastatinCytochrome P450 3A7enzyme
DB01076AtorvastatinMultidrug resistance protein 1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01076AtorvastatinMultidrug resistance-associated protein 4transporter
DB01076AtorvastatinMultidrug resistance-associated protein 5transporter
DB01076AtorvastatinMultidrug resistance-associated protein 1transporter
DB01076AtorvastatinCytochrome P450 2B6enzyme
DB01076AtorvastatinCytochrome P450 2C8enzyme
DB01076AtorvastatinAryl hydrocarbon receptortarget
DB01076AtorvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01076AtorvastatinUDP-glucuronosyltransferase 1-1enzyme
DB01076AtorvastatinUDP-glucuronosyltransferase 1-3enzyme
DB01076AtorvastatinCanalicular multispecific organic anion transporter 1transporter
DB01076AtorvastatinBile salt export pumptransporter
DB01076AtorvastatinSerum albumincarrier
DB01076AtorvastatinHistone deacetylase 2target
DB01076AtorvastatinNuclear receptor subfamily 1 group I member 3target
DB01098Rosuvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01098RosuvastatinCytochrome P450 2C9enzyme
DB01098RosuvastatinMultidrug resistance-associated protein 4transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01098RosuvastatinCystine/glutamate transportertransporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01098RosuvastatinBile salt export pumptransporter
DB01098RosuvastatinATP-binding cassette sub-family G member 2transporter
DB01098RosuvastatinSerum albumincarrier
DB01098RosuvastatinCanalicular multispecific organic anion transporter 1transporter
DB01098RosuvastatinSolute carrier family 22 member 8transporter
DB01098RosuvastatinSodium/bile acid cotransportertransporter
DB01098RosuvastatinIntegrin alpha-Ltarget
DB04377Meglutol3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB09302AlirocumabProprotein convertase subtilisin/kexin type 9target